Brodactam IV

Introduction
Brodactam IV is a combination of two antibiotics. It is used to treat various types of bacterial infections. It fights against the infection by killing the microorganisms. Brodactam IV is generally administered by a healthcare professional and should not be self-administered. Depending on the severity of your underlying illness, your doctor will decide the precise dose and schedule as per which this injection is to be given. It is strictly advised to be used as per the doctor’s prescription. Some of the common side effects of this medicine include nausea, vomiting, diarrhea, and rash. Additionally, you may notice some injection site reactions like pain, swelling, or redness. You should consult your doctor if these side effects do not get better with time and persist for a longer duration. Before using the medicine, you should tell your doctor if you are allergic to any antibiotics or have any kidney or liver problems. Your doctor may change the dose or prescribe a different medicine. This medicine is generally considered safe to use during pregnancy and breastfeeding if used under a doctor’s supervision.

_
Uses of Brodactam IV
Bacterial infections
Side effects of Brodactam IV
Common
Nausea
Vomiting
Diarrhea
Rash
Allergic reaction
How to use Brodactam IV
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Brodactam IV works
Brodactam IV is a combination of two medicines: Piperacillin and Tazobactum. Piperacillin is an antibiotic. It works by preventing the formation of the bacterial protective covering which is essential for the survival of bacteria. Tazobactum is a beta-lactamase inhibitor which reduces resistance and enhances the activity of Piperacillin against bacteria.
Quick Tips
You have been prescribed this combination medicine to treat bacterial infections even if they have developed resistance.
Finish the prescribed course, even if you start to feel better. Stopping it early may make the infection come back and harder to treat.
Diarrhea may occur as a side effect. Taking probiotics along with Brodactam IV may help. Talk to your doctor if you notice bloody stools or develop abdominal cramps.
Stop taking Brodactam IV and inform your doctor immediately if you develop an itchy rash, swelling of the face, throat or tongue or breathing difficulties while taking it.
Brief Description
Indication
Septicaemia, Nosocomial pneumonia
Administration
Reconstitution Reconstitute initially (2.25 g in 10 mL, 4.5 g in 20 mL) w/ water for inj, glucose 5% or NaCl 0.9%, then further dilute to 50-150 mL w/ compatible infusion soln. IV Administration Infusion over 30 min

_
Adult Dose
Intravenous Nosocomial pneumonia Adult: Each vial contains 4.5 g (piperacillin 4 g and tazobactam 0.5 g): 4.5 g 6 hrly for 5-14 days by infusion over 30 min. When used empirically, combination w/ aminoglycoside or antipseudomonal fluoroquinolone is recommended. Empiric therapy for febrile neutropenic patients Adult: Each vial contains 4.5 g (piperacillin 4 g and tazobactam 0.5 g): 4.5 g 6 hrly for 5-14 days by infusion over 30 min. Complicated intra-abdominal infections Adult: Each vial contains 4.5 g (piperacillin 4 g and tazobactam 0.5 g): 4.5 g 8 hrly for 5-14 days by infusion over 30 min. Complicated urinary tract infections; Skin and soft tissue infections Adult: Each vial contains 4.5 g (piperacillin 4 g and tazobactam 0.5 g): 4.5 g 8 hrly for 5-14 days by infusion over 30 min.

_
Child Dose
Intravenous Child: Usually <40 kg: 240–300 mg PIP/kg/day 8 hourly Alternatively Nosocomial pneumonia Child: 2-12 yr 90 mg/kg (piperacillin 80 mg/kg and tazobactam 10 mg/kg) 6 hrly for 5-14 days by infusion over 30 min. Max: 4.5 g per dose; >12 yr Same as adult dose. Empiric therapy for febrile neutropenic patients Child: 2-12 yr 90 mg/kg (piperacillin 80 mg/kg and tazobactam 10 mg/kg) 6 hrly for 5-14 days by infusion over 30 min. Max: 4.5 g per dose; >12 yr Same as adult dose. Complicated intra-abdominal infections Child: 2-12 yr 112.5 mg/kg (piperacillin 100 mg and tazobactam 12.5 mg) 8 hrly for 5-14 days by infusion over 30 min. Max: 4.5 g per dose.

_
Renal Dose
Renal impairment: Haemodialysis patients: 2.25 g 12 hrly; additional dose of 0.75 g after each dialysis session. CAPD: 2.25 g 12 hrly. CrCl (ml/min) Dosage Recommendation <20 2.25 g 8 hrly. 20-40 2.25 g 6 hrly. _ Contraindication Hypersensitivity. Mode of Action Piperacillin has an antimicrobial activity against a wide range of gm-ve organisms including K. pneumoniae, P. aeruginosa, Enterobacteriaceae and against gm+ve organisms eg E. faecalis and B. fragilis. Tazobactam is a penicillanic acid sulfone derivative with beta-lactamase inhibitory properties. In combination, tazobactam enhances the activity of piperacillin against beta-lactamase-producing bacteria. Precaution Pregnancy and lactation, pseudomembranous colitis. Assess hematopoietic function periodically. Perform periodic electrolyte determinations in patients with low K reserves. Increased risk of fever and rash in patients with cystic fibrosis. Increased risk of bleeding manifestations. Prolonged treatment may increase risk of superinfections. Convulsions or neuromuscular excitability may occur when high doses are used, especially in renally impaired patients. Renal impairment. Lactation: Low concentrations of piperacillin excreted in breast milk; tazobactam unknown; use caution _ Side Effect >10% Diarrhea (7-11%) 1-10% Constipation (1-8%),Headache (1-8%),Insomnia (4-7%),Nausea (2-7%),Fever (2-5%),Oral candidiasis (2-4%),Rash (2-4%),Vomiting (2-4%),Dyspepsia (3%),Pruritus (3%),Pain (2-3%),Hypertension (2%),Leukopenia (1%),Thrombocytopenia (1.4%) <1% Anaphylaxis,Agranulocytosis,Thrombocytopenia,Eosinophilia,Leukopenia,Positive Coombs test,Prolonged PT and PTT,Transient LFT and creatinine elevations.Seizure,Pulmonary edema,Pulmonary embolism _ Interaction Interacts w/ high doses of heparin, oral anticoagulants or other drugs that affect blood coagulation or thrombocyte function. Prolongs the neuromuscular blockade of vecuronium and non-depolarising muscle relaxants. Prolongs half-lives w/ probenecid. Increased risk of methotrexate toxicity.